WIKIMEDIA, NATIONAL INSTITUTES OF HEALTHFollowing an announcement in April that its gene therapy product does not work, the San Diego-based biotech Celladon is halving its staff and suspending research and development operations.
“Celladon was once among the highest profile companies in the gene therapy space, developing a treatment for the common ailment of heart failure in contrast to the rare disease R&D that has largely dominated the field,” according to Fierce Biotech. “The plan now is to find a merger or sale that can salvage some value…”
Celladon’s therapy, Mydicar, used a viral vector to deliver the gene encoding an enzyme that ensures proper functioning of cardiomyocytes in patients with heart failure. However, when compared to a placebo, Mydicar did not prevent the progression of heart failure or hospitalizations.
“Our Board of Directors has unanimously determined that seeking a merger or sale, in lieu of further development of...
Interested in reading more?
The Scientist ARCHIVES
Become a Member of
